<DOC>
	<DOCNO>NCT02641730</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety guselkumab treatment participant palmoplantar pustulosis .</brief_summary>
	<brief_title>An Efficacy Safety Guselkumab Participants With Palmoplantar Pustulosis</brief_title>
	<detailed_description>This phase 3 , randomize ( study drug assign chance ) , double-blind ( neither physician participant know name assigned drug ) , multicenter ( one hospital work medical research study ) placebo-controlled ( inactive substance compare medication test whether medication real effect clinical study ) study participant palmoplantar pustulosis . The study consist 3 phase : screening phase ( 6 week ) , treatment period ( week 0 - week 60 ) observational period ( week 84 ) . Participants assign 1 3 treatment group ( 200 milligram [ mg ] guselkumab , 100 mg guselkumab placebo group ) use stratified block randomization method 1:1:1 ratio Week 0 Group III ( placebo ) participant allocate 1:1 ratio 1 2 treatment group Week 16 . Participants primarily assess change baseline Palmo-Plantar Pustular Area Severity Index ( PPPASI ) total score Week 16 . Safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Has diagnosis palmoplantar pustulosis ( without pustulotic arthroosteitis , concurrent extrapalmoplantar lesion ) least 24 week screen Has &gt; = 12 PPPASI total score screen baseline Has moderate severe pustules/vesicle palm sol ( &gt; = 2 PPPASI severity score ) screen baseline Has inadequate response treatment topical steroid and/or topical vitamin D3 derivative preparation and/or phototherapy and/or systemic etretinate prior screen . Inadequate response define case judge investigator Before first administration study drug , woman must either : Not childbearing potential : premenarchal ; postmenopausal Of childbearing potential practicing highly effective method birth control Has diagnosis plaquetype psoriasis Has obvious improvement screening ( &gt; = 5 PPPASI total score improvement screen ) Has history current sign symptom severe , progressive , uncontrolled renal , cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance Has unstable cardiovascular disease , define recent clinical deterioration ( eg , unstable angina , rapid atrial fibrillation ) last 12 week cardiac hospitalization within last 12 week screen Currently malignancy history malignancy within 5 year screen ( exception nonmelanoma skin cancer adequately treat evidence recurrence least 12 week screen cervical carcinoma situ treat evidence recurrence least 12 week screen )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Guselkumab</keyword>
	<keyword>CNTO 1959</keyword>
	<keyword>Placebo</keyword>
	<keyword>Palmoplantar Pustulosis</keyword>
</DOC>